# The Cooper Companies, Inc. (COO) Stock Analysis: Unveiling a 27% Upside Potential

- Link: https://www.directorstalkinterviews.com/the-cooper-companies-inc-coo-stock-analysis-unveiling-a-27-upside-potential/4121212460
- Published: 2025-08-18T10:21:25+01:00
- Author: Madison Wilson

For investors looking to delve into the healthcare sector, The Cooper Companies,
Inc. (NYSE: COO) presents a compelling opportunity, particularly with a potential
upside of 27.31%. Headquartered in San Ramon, California, this $14.62 billion market
cap company stands as a stalwart in the medical instruments and supplies industry,
with a focus on eye care and women’s health.

### Navigating the Price and Valuation Landscape

Currently trading at $73.26, COO’s price is notably below its 52-week high of $111.23,
reflecting a potential for growth. The stock’s 52-week range of $66.91 to $111.23
highlights some volatility, yet also an opportunity for investors to capitalize 
on its current lower price. The forward P/E ratio of 16.52 suggests a reasonable
valuation relative to expected earnings, although the absence of trailing P/E and
PEG ratios calls for a cautious evaluation of its past profitability and growth 
expectations.

### Performance Metrics: A Look at Growth and Profitability

The Cooper Companies showcases a robust revenue growth of 6.3%, underscoring its
ability to expand in a competitive market. With earnings per share (EPS) of 2.07
and a return on equity (ROE) of 5.15%, COO demonstrates a moderate level of profitability.
The company also maintains a healthy free cash flow of approximately $228 million,
which can be pivotal for future investments and strategic initiatives.

### A Strategic Focus on Healthcare Innovation

The company’s operations are divided between CooperVision and CooperSurgical. CooperVision
is renowned for its advanced contact lenses that address various vision issues, 
while CooperSurgical provides products and services in family and women’s healthcare,
including fertility treatments and contraceptive solutions. This diversification
in product offerings not only enhances its market reach but also fortifies its position
in the healthcare sector.

### Analyst Ratings and Potential Upside

Analyst sentiment towards COO is largely positive, with 11 buy ratings and 6 hold
ratings, and no sell ratings, reflecting confidence in its growth trajectory. The
average target price of $93.27 suggests a substantial upside from current levels,
reinforcing the stock’s attractiveness. Moreover, the target price range of $76.00
to $105.00 indicates room for significant appreciation.

### Technical Indicators: A Snapshot of Market Sentiment

From a technical perspective, COO’s 50-day moving average of $71.94, slightly below
the current price, suggests near-term stability. However, its 200-day moving average
stands at $85.04, indicating potential for a longer-term recovery. The Relative 
Strength Index (RSI) of 83.98 suggests the stock is in overbought territory, which
may hint at a pullback, yet could also signal strong momentum.

### Dividend Considerations

While COO does not currently offer a dividend yield, maintaining a payout ratio 
of 0.00%, it channels its resources into growth and innovation, which could yield
substantial returns for investors focused on capital appreciation.

Investors eyeing The Cooper Companies should weigh its growth potential against 
market conditions and personal investment strategies. With a strong foothold in 
essential healthcare markets and a promising upside, COO remains a stock to watch
for those seeking exposure to the medical instruments and supplies sector.

Share on: